Provider Continuity Prior to the Diagnosis of Advanced Lung Cancer and End-of-Life Care

Gulshan Sharma¹*, Yue Wang², James E. Graham³, Yong-Fang Kuo⁴, James S. Goodwin⁵

¹ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, United States of America, ² Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, United States of America, ³ Department of Rehabilitation Sciences, University of Texas Medical Branch, Galveston, Texas, United States of America, ⁴ Department of PMCH Epidemiology and Biostatistics, University of Texas Medical Branch, Galveston, Texas, United States of America, ⁵ Department of Internal Medicine, Sealy Center of Aging, University of Texas Medical Branch, Galveston, Texas, United States of America

Abstract

Background: Little is known about the effect of provider continuity prior to the diagnosis of advanced lung cancer and end-of-life care.

Methods: Retrospective analysis of 69,247 Medicare beneficiaries aged 67 years or older diagnosed with Stage IIIb or IV lung cancer between January 1, 1993 and December 31, 2005 who died within two years of diagnosis. We examined visit patterns to a primary care physician (PCP) and/or any provider one year prior to the diagnosis of advanced lung cancer as measures of continuity of care. Outcome measures were hospitalization, ICU use and chemotherapy use during the last month of life, and hospice use during the last week of life.

Results: Seeing a PCP or any provider in the year prior to the diagnosis of advanced lung cancer increased the likelihood of hospitalization, ICU care, chemotherapy and hospice use during the end of life. Patients with 1–3, 4–7 or >7 visits to their PCP in the year prior to the diagnosis of lung cancer had 1.0 (reference), 1.08 (95% CI; 1.04–1.13), and 1.14 (95% CI; 1.08–1.19) odds of hospitalization during the last month of life, respectively. Odds of hospice use during the last week of life were higher in patients with visits to multiple PCPs (OR 1.10: 95% CI; 1.06–1.15) compared to those whose visits were all to the same PCP.

Conclusion: Provider continuity in the year prior to the diagnosis of advanced lung cancer was not associated with lower use of aggressive care during end of life. Our study did not have information on patient preferences and result should be interpreted accordingly.

Introduction

Outpatient provider continuity is central to the “medical home” concept of the Patient Protection and Affordable Care Act and is key to good medical care[1]. It is associated with improved patient satisfaction,[2] increased use of appropriate preventive health services[3–7], greater medication compliance, lower hospitalization rates,[8–12] less emergency department use[13] and fewer duplicate tests.[14] Moreover, continuity of care with a primary care physician (PCP) has shown substantial reductions in mortality among older adults.[15]

Continuity is beneficial for cancer patients both prior to and after diagnosis. Pre-diagnosis continuity leads to diagnoses at earlier stages.[16] PCP continuity after cancer diagnosis increases the likelihood of receiving guideline concordant therapy,[17] decreases the likelihood of emergency room visits in the last six months of life,[10] and increases the likelihood of dying at home.[19] Patients visited by their PCP during their last hospitalization (outpatient to inpatient provider continuity) are less likely to receive Intensive Care Unit (ICU) care.[20]

Studies of the effects of continuity on end-of-life care in cancer patients are primarily limited to patients already diagnosed with cancer. We were interested in whether the continuity established prior to this life- and care-altering event (diagnosis of advanced lung cancer) has enduring effects on the end-of-life medical care these patients received. Our hypothesis was that provider continuity prior to the diagnosis of advanced cancer is associated with lower hospitalization, less ICU use, less chemotherapy use and higher hospice use at the end of life. These measures are considered indicators of potentially appropriate care. We used a national sample of newly-diagnosed advanced lung cancer patients to examine the effect of provider continuity prior to the diagnosis of advanced lung cancer on end-of-life medical care.
Methods

Data Source

This is a retrospective study of advanced lung cancer patients identified from the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database for the years 1993–2005. We included the 13 SEER registry geographic regions: the states of Connecticut, Hawaii, Utah, New Mexico, Iowa, California, Kentucky, Louisiana and New Jersey; rural Georgia; and the municipalities of Detroit, MI; Seattle, WA; and Atlanta, GA. For all incident cancers diagnosed in these areas, the SEER registries collect information on patient demographics, tumor characteristics, stage at diagnosis, date of diagnosis, therapy received within four months of diagnosis, and date and cause of death.

Through a collaborative project between the National Cancer Institute and the Centers for Medicare and Medicaid Services (CMS), entitlement information and claims data from the Medicare program were linked to the SEER data for cancer patients aged 65 and older. Medicare eligibility could be identified for 93% of SEER patients aged 65 and older.

Data from multiple files were used for this study: 1) the Patient Entitlement and Diagnosis File (SEER registry data and Medicare entitlement information); 2) Medicare Provider Analysis and Review file (MEDPAR, hospital inpatient and skilled nursing facility stays); 3) Outpatient Standard Analytic File (hospital outpatient services); 4) Physician/Supplier File (physician and other medical services); and 5) Hospice File.

Study Cohort

Eligible subjects selected from the Patient Entitlement and Diagnosis File included patients who were: 1) diagnosed with stage III B or stage IV lung cancer from 1993 – 2005 (N = 143,515), 2) 67 years or older at the time of diagnosis (N = 113,183), 3) enrolled in Medicare Parts A and B for at least two years prior to death (N = 76,434), and 4) died within two years of diagnosis and had continuous enrollment in Parts A and B until death (N = 69,427). To have completeness of information in the Medicare files of these patients, we excluded those enrolled in an HMO at any time from two years before date of diagnosis through date of death.

Measures

Patient characteristics. Patients’ sociodemographic characteristics were obtained from the SEER data and included the following variables: age (67–74, 75–84, ≥85 years), gender (male, female), race/ethnicity (non-Hispanic white, Black, Hispanic, Other), diagnosis year and SEER geographic region. Socioeconomic status was based on whether the patient was eligible for state buy-in coverage provided by the Medicaid program for at least one month during the year of diagnosis. Comorbidity was measured with the Charlson comorbidity score (0, 1, 2, 3) using all Medicare claims from the year prior to diagnosis.[9] Survival time after diagnosis was measured in months (<1, 1–2, 3–4, 5–6, 7–12, 13–18, 19–24). We also included the number of hospitalizations (0, 1, ≥2) in the 13–24 months before diagnosis as an independent variable.

Definition of study variables. HCFA Common Procedure Terminology (CPT) evaluation and management codes 99201 to 99205 (new patient) and 99221 to 99225 (established patient encounters) were used to establish outpatient visits. Individual providers were determined using the Unique Provider Identification Number (UPIN). We examined visits to PCPs and to any provider. PCPs included those in: family medicine, general practice, internal medicine and geriatrics. For female patients, OB/Gyn was included. Any provider was defined as a primary physician or an internal medicine specialist. To avoid overestimation of visits and continuity, we excluded visits that occurred one month prior to the diagnosis of lung cancer. Visits between months −2 to −13 constitute a year prior to diagnosis (herein referred to as the year prior to diagnosis). In some analyses we assessed visits in months −13 to −24 prior to diagnosis.

Provider continuity. We examined visit patterns for PCPs and for any provider separately as a measure of continuity. Visits to a PCP were defined as the total number of PCP visits in the year prior to diagnosis. (0, 1–3, 4–7, ≥7). Number of PCPs was defined as the number of unique PCPs seen in the year prior to diagnosis. Having more than one PCP was defined as seeing multiple PCPs.

Visits to any provider was defined as the total number of visits to any physician in the year prior to diagnosis (0, 1–3, 4–7, ≥7). Number of any providers seen was defined as the number of unique providers seen in the year prior to diagnosis (unique UPINs). Seeing more than one physician was defined as having multiple providers. We assigned a PCP or a provider to a given patient with whom he/she had the majority of outpatient visits in the year prior to diagnosis of advanced lung cancer.

We also used the time exposure method of continuity as defined by Wolinsky et al.[21] To calculate this measure, we expanded the pre-diagnosis period to two years and defined continuity (yes/no) as having visited the same physician twice within any eight months during that time.

Outcomes. Our outcome of interest was medical care during the end of life. We examined hospitalization, ICU use, and chemotherapy use during the last month of life, and hospice use during the last week of life. The first three were considered indicators of potentially aggressive (overtreatment) end of life care and hospice use as appropriate end of life care.

The study was approved by the Institutional Review Board of the University of Texas Medical Branch, Galveston, TX. De-identified data provided by SEER-Medicare were analyzed and no prior informed consent was required. The manuscript was approved by SEER-Medicare for anonymity prior to submission for publication.

Statistical Analysis. The chi square test was used to compare end-of-life care by patient characteristics. Multivariate logistic regression analyses were used to assess whether different continuity measures affected end-of-life care (yes/no). Both patient characteristics (including age, gender, race, diagnosis year, geographic region, comorbidity, survival time, number of hospitalizations in the 13–24 months before diagnosis) and continuity measures (having a PCP, number of PCPs, total number of visits to PCP, total number of visits to assigned PCP, time exposure method of continuity) were added to the final model. All analyses were performed with SAS version 9.2 (SAS, Inc., Cary, NC). All reported p-values were two-sided and p<0.05 was considered statistically significant.

Results

Table 1 presents the baseline characteristics of the cohort and medical care measures (hospitalization during the last month of life, ICU use during the last month of life, chemotherapy use during the last month of life, and hospice use during the last week of life) in 69,427 patients diagnosed with advanced lung cancer who were followed for 24 months. Younger patients, males, non-whites and those with low socioeconomic status were more likely to be hospitalized and to receive ICU care during the last month of life. Hospice use was more common in females, non-Hispanic whites and those with higher socioeconomic status. Patients with
Table 1. Baseline characteristics and percent of patients experiencing end of life care measures in Medicare patients with advanced lung cancer, 1993–2005.

| Characteristic                        | N     | Hospitalized | ICU | Chemotherapy | Hospice |
|---------------------------------------|-------|--------------|-----|--------------|---------|
| All Subjects                          | 69427 | 50.4         | 13.0| 12.8         | 45.6    |
| Age at Diagnosis (yrs)                |       |              |     |              |         |
| 66–74                                 | 30169 | 53.5         | 14.5| 16.6         | 44.5    |
| 75–84                                 | 31478 | 49.2         | 12.5| 11.3         | 46.6    |
| >= 85                                 | 7780  | 43.1         | 9.4 | 3.9          | 46.0    |
| Gender                                |       |              |     |              |         |
| Male                                  | 37718 | 51.9         | 13.8| 14.0         | 42.7    |
| Female                                | 31709 | 48.5         | 12.0| 11.3         | 49.1    |
| Race                                  |       |              |     |              |         |
| Non-Hispanic White                    | 58453 | 49.6         | 12.3| 13.3         | 47.1    |
| Black                                 | 2227  | 54.5         | 16.3| 9.0          | 39.0    |
| Hispanic                              | 5854  | 52.7         | 17.2| 12.2         | 42.4    |
| Other                                 | 2893  | 56.3         | 18.1| 10.4         | 31.6    |
| Low Socioeconomic Status              |       |              |     |              |         |
| No                                    | 58638 | 50.1         | 12.4| 13.6         | 47.1    |
| Yes                                   | 10789 | 52.1         | 16.2| 8.2          | 37.8    |
| Charlson Comorbidity Score            |       |              |     |              |         |
| 0                                     | 35795 | 48.6         | 11.6| 13.3         | 46.9    |
| 1                                     | 18663 | 51.6         | 13.6| 13.2         | 46.3    |
| 2                                     | 8237  | 51.9         | 15.3| 11.8         | 43.2    |
| >=3                                   | 6732  | 54.6         | 16.3| 10.1         | 40.3    |
| Times hospitalized in the 13–24 months before diagnosis |       |              |     |              |         |
| 0                                     | 57297 | 50.0         | 12.7| 13.2         | 45.9    |
| 1                                     | 8054  | 51.2         | 13.8| 11.2         | 45.2    |
| >=2                                   | 4076  | 53.8         | 16.1| 10.3         | 42.2    |
| Survival time (months)                |       |              |     |              |         |
| 0–1                                   | 15445 | 45.2         | 13.1| 4.3          | 26.1    |
| 2–3                                   | 19052 | 59.6         | 16.0| 14.0         | 46.6    |
| 4–6                                   | 13373 | 48.8         | 11.7| 16.6         | 51.9    |
| 7–12                                  | 13304 | 48.0         | 11.0| 15.9         | 54.3    |
| 13–18                                 | 5755  | 46.2         | 11.3| 15.4         | 55.8    |
| 19–24                                 | 2498  | 43.1         | 11.0| 13.4         | 56.2    |
| SEER site                             |       |              |     |              |         |
| Connecticut                           | 5916  | 50.3         | 9.5 | 12.9         | 38.5    |
| Detroit                               | 8308  | 57.4         | 16.0| 12.1         | 51.0    |
| Hawaii                                | 1149  | 49.9         | 11.9| 8.9          | 38.1    |
| Iowa                                  | 6604  | 45.6         | 6.2 | 11.0         | 52.0    |
| New Mexico                            | 1594  | 43.0         | 11.7| 10.2         | 50.8    |
| Seattle                               | 5201  | 44.9         | 9.0 | 12.8         | 41.0    |
| Utah                                  | 1259  | 36.1         | 9.2 | 9.3          | 48.8    |
| Atlanta                               | 2562  | 48.8         | 10.5| 16.2         | 47.1    |
| Rural Georgia                         | 232   | 50.4         | 9.9 | 16.8         | 44.8    |
| Kentucky                              | 5248  | 49.3         | 13.4| 13.2         | 51.8    |
| Louisiana                             | 4035  | 51.9         | 10.9| 11.7         | 50.6    |
| New Jersey                            | 7446  | 55.6         | 16.9| 17.8         | 45.8    |
| California                            | 19873 | 50.2         | 15.8| 12.1         | 41.5    |
| Diagnosis Year                        |       |              |     |              |         |
| 1993                                  | 3394  | 51.4         | 8.9 | 7.3          | 28.3    |
lower comorbidity scores were less likely to be hospitalized or to receive ICU care.

There was large variation in the receipt of aggressive end-of-life care and hospice care across SEER sites. Relative to other areas, hospitalization was more common in the Detroit metropolitan area; ICU use and chemotherapy use during the last month of life were more common in New Jersey; and hospice use was more common in Iowa. ICU use increased from 8.9% in 1993 to 15.9% in 2005 (p<0.0001). Similarly, hospice use increased from 28.3% in 1993 to 54.1% in 2005 (p<0.0001). Aggressive end-of-life care was more common in patients with shorter survival time. Patients who died within three months of diagnosis of advanced lung cancer were more likely to be hospitalized and receive ICU care during the last month of life. By contrast, hospice use was more common in those with longer survival time: 26.1% in those who survived during the last week of life, respectively. The odds of hospitalization, ICU use and chemotherapy use during the last week of life, as well as hospice use during the last week of life. The association between provider continuity and number of outpatient visits to PCPs was inconsistent.

Table 2 presents the bivariate analyses for several measures of provider continuity and end-of-life care. Seeing a PCP in the year prior to a diagnosis of advanced lung cancer increased the likelihood of hospitalization, ICU care during the last month of life, as well as hospice use during the last week of life. The association between end-of-life care and number of provider continuity prior to the diagnosis and number of outpatient visits to PCPs was inconsistent.

Table 3 shows the results of multivariable analyses of the association between provider continuity and end-of-life care measures. Seeing a PCP or any provider and having continuity with a PCP or any provider was associated with increased risk of hospitalization, ICU use and chemotherapy use during the last month of life, as well as hospice use during the last week of life. The odds of hospitalization and ICU use in the last month of life increased stepwise with an increase in number of visits. For example patients with 1–3, 4–7 or >7 visits to their PCP in the year prior to the diagnosis of lung cancer had 1.0 (reference), 1.08 (95% CI; 1.04–1.13), and 1.14 (95% CI; 1.08–1.19) odds of hospitalization during the last month of life, respectively. The results were similar for analyses limited to patients with an identifiable PCP. There was no clear association with hospice use during the last week of life, except for higher odds in patients with outpatient visits to multiple PCPs compared to those whose visits were all to the same PCP. Patients who made more visits (≥7) to their assigned PCP had 0.91 (0.86–0.96) lower odds of hospice use during the last week of life. There was no difference in end-of-life care measures using the time exposure method.

One potential confounder in analysis of pre-diagnosis continuity of care with post-diagnosis care is that earlier provider visits, precipitated by symptoms of the yet-undiagnosed cancer, may affect the estimation of true continuity of care. To address that possibility, we repeated all analyses using measures of provider visits generated in the period 13–24 months prior to the diagnosis of advanced lung cancer. Those analyses produced very similar results to those shown for the analysis using the 2–13 months prior to diagnosis.

### Discussion

Prior studies on continuity and end-of-life care in patients with cancer have focused on patient-provider patterns following cancer diagnosis.[18–20;22–24] Continuity of care after diagnosis seems to matter. However, whether the continuity established prior to diagnosis of advanced lung cancer has an effect on end-of-life medical care is unknown. We examined associations between several measures of provider continuity prior to the diagnosis and medical care received during end of life.

Provider continuity in the year prior to the diagnosis of advanced lung cancer was not substantially associated with less aggressive medical care during end-of-life care. However, survival time had a significant effect on end-of-life care. Patients with shorter survival were more likely to receive aggressive care whereas those with longer survival were likely to receive hospice care at the end of life. Long term survivors likely represent individuals with lung cancer sensitive to the standard initial chemotherapy and radiotherapy. These individuals are unlikely to benefit from additional treatment later in the course of their disease; thus, they are more likely to opt for hospice care. Moreover, longer survivors also had more time to cope with their terminal illness and perhaps are better prepared for end of life.
Hospice care focuses on palliative care and symptom management rather than disease treatment. Our study showed both aggressive and palliative care increased over time, similar to prior reports [20;25]. Patients are choosing both types of care, rather than one or the other, regardless of provider continuity. These results are similar to a Kronman et al. study which showed no clear effect of PCP visits on hospice care.[26] A recent randomized control trial showed that patients with advanced lung cancer who received early palliative care consultation in addition to standard treatment were less likely to receive aggressive care during end of life.

### Table 2. Provider continuity in the year prior to diagnosis of advanced lung cancer and end-of-life care.

| Continuity Measure | N     | Hospitalized¹ | ICU¹ | Chemotherapy¹ | Hospice² |
|--------------------|-------|---------------|------|---------------|---------|
| All Subjects       | 69427 | 50.4          | 13.0 | 12.8          | 45.6    |
| Saw a PCP          | No    | 22106         | 47.3 | 12.3          | 11.1    | 41.4    |
|                    | Yes   | 47321         | 51.8 | 13.3          | 13.6    | 47.6    |
| Number of PCPs seen| 0     | 22106         | 47.3 | 12.3          | 11.1    | 41.4    |
|                    | 1     | 33289         | 51.6 | 13.2          | 13.7    | 46.9    |
|                    | >1    | 14032         | 52.4 | 13.7          | 13.3    | 49.3    |
| Total number of visits to PCP | 0     | 22106         | 47.3 | 12.3          | 11.1    | 41.4    |
|                    | 1–3   | 20193         | 50.0 | 12.4          | 14.0    | 48.2    |
|                    | 4–7   | 17229         | 52.5 | 13.0          | 13.8    | 48.2    |
|                    | >7    | 9899          | 54.3 | 15.9          | 12.3    | 45.2    |
| Number of visits to an assigned PCP (N = 47321) | 1–3   | 23328         | 50.3 | 12.5          | 14.0    | 48.6    |
|                    | 4–7   | 16445         | 52.4 | 13.3          | 13.7    | 48.0    |
|                    | >7    | 7548          | 55.0 | 16.3          | 12.2    | 43.5    |
| Time exposure method continuity of PCP³ | No    | 25745         | 47.8 | 12.2          | 11.5    | 42.2    |
|                    | Yes   | 43682         | 51.9 | 13.5          | 13.6    | 47.6    |
| Saw any provider   | No    | 13300         | 43.3 | 10.8          | 9.2     | 39.7    |
|                    | Yes   | 56127         | 52.1 | 13.5          | 13.6    | 47.0    |
| Number of any provider seen | 0     | 13300         | 43.3 | 10.8          | 9.2     | 39.7    |
|                    | 1     | 21880         | 50.5 | 12.5          | 12.4    | 45.4    |
|                    | >1    | 34247         | 53.1 | 14.2          | 14.5    | 48.0    |
| Total number of visits to any provider | 0     | 13300         | 43.3 | 10.8          | 9.2     | 39.7    |
|                    | 1–3   | 17226         | 48.9 | 11.8          | 13.1    | 47.1    |
|                    | 4–7   | 18728         | 51.7 | 12.6          | 13.7    | 48.4    |
|                    | >7    | 20173         | 55.0 | 15.9          | 14.0    | 45.7    |
| Number of Visits to a assigned provider (N = 56127) | 1–3   | 25325         | 49.8 | 12.1          | 13.7    | 48.3    |
|                    | 4–7   | 20875         | 53.0 | 13.7          | 13.9    | 47.6    |
|                    | >7    | 9927          | 55.9 | 16.7          | 12.8    | 42.7    |
| Time exposure method continuity of any provider³ | No    | 16727         | 44.4 | 10.9          | 10.2    | 40.8    |
|                    | Yes   | 52700         | 52.3 | 13.7          | 13.6    | 47.1    |

1 = in last month of life.  
2 = in last week of life.  
ICU, intensive care unit; PCP, primary care physician.  
3 = Time exposure method of continuity is defined as having visited the same physician twice within any eight months over the two years prior to the diagnosis of lung cancer.

1 = in last month of life.  
2 = in last week of life.  
ICU, intensive care unit; PCP, primary care physician.  
3 = Time exposure method of continuity is defined as having visited the same physician twice within any eight months over the two years prior to the diagnosis of lung cancer.
life and lived 2.6 months longer than those who received standard treatment alone [27]. The benefits seen in this study likely arise from better understanding of their disease process and more time to declare their end of life choices.

Our findings are consistent with the study by Kronman et al. of decedent Medicare beneficiaries; compared to patients with no PCP visits during the 7–18 months prior to death, those with ≥9 PCP visits were hospitalized more frequently (0.9 versus 1.3

| Table 3. Multivariable analyses of the associations between provider continuity measures and end-of-life care. |
|---|
| **End of life care measures** | **Hospitalized**<sup>1</sup> OR (95% CI) | **ICU**<sup>1</sup> OR (95% CI) | **Chemotherapy**<sup>1</sup> OR (95% CI) | **Hospice**<sup>2</sup> OR (95% CI) |
| **PCP** Saw a PCP | | | | |
| No | 0.82 (0.79,0.84) | 0.88 (0.84,0.93) | 0.77 (0.73,0.81) | 0.84 (0.82,0.87) |
| Yes ref | ref | ref | ref | |
| Number of PCPs seen | | | | |
| 0 | 0.82 (0.80,0.85) | 0.89 (0.84,0.94) | 0.77 (0.72,0.81) | 0.87 (0.84,0.90) |
| 1 | ref | ref | ref | |
| > 1 | 1.04 (1.00,1.08) | 1.03 (0.97,1.10) | 1.00 (0.94,1.06) | **1.10 (1.06,1.15)** |
| Total visits to PCP | | | | |
| 0 | 0.86 (0.83,0.89) | 0.91 (0.85,0.96) | 0.78 (0.73,0.82) | 0.85 (0.81,0.88) |
| 1–3 | ref | ref | ref | |
| 4–7 | 1.08 (1.04,1.13) | 0.99 (0.93,1.06) | 1.03 (0.97,1.10) | 1.02 (0.97,1.06) |
| > 7 | **1.14 (1.08,1.19)** | **1.15 (1.07,1.24)** | 1.01 (0.94,1.10) | 0.97 (0.92,1.02) |
| Number of visits to assigned PCP | | | | |
| 1–3 | ref | ref | ref | |
| 4–7 | 1.07 (1.03,1.12) | 1.01 (0.95,1.07) | 1.05 (0.99,1.11) | 1.00 (0.96,1.05) |
| > 7 | **1.16 (1.09,1.22)** | **1.17 (1.08,1.26)** | 1.02 (0.94,1.12) | **0.91 (0.86,0.96)** |
| Time exposure method continuity of PCP<sup>3</sup> | | | | |
| No | 0.92 (0.83,1.02) | 0.93 (0.79,1.09) | 1.09 (0.94,1.26) | 0.94 (0.84,1.04) |
| Yes ref | ref | ref | ref | |
| Any Provider | | | | |
| Saw any provider | | | | |
| No | 0.68 (0.65,0.71) | 0.77 (0.72,0.82) | 0.61 (0.57,0.66) | 0.8 (0.76,0.83) |
| Yes ref | ref | ref | ref | |
| Number of any providers seen | | | | |
| 0 | 0.72 (0.68,0.75) | 0.81 (0.75,0.86) | 0.67 (0.62,0.72) | 0.83 (0.79,0.87) |
| 1 | ref | ref | ref | |
| > 1 | **1.1 (1.07,1.14)** | **1.09 (1.04,1.15)** | **1.18 (1.12,1.24)** | **1.09 (1.05,1.13)** |
| Total visits to any provider | | | | |
| 0 | 0.75 (0.71,0.78) | 0.83 (0.77,0.89) | 0.67 (0.62,0.72) | 0.81 (0.77,0.85) |
| 1–3 | ref | ref | ref | |
| 4–7 | **1.12 (1.07,1.17)** | 1.04 (0.98,1.11) | **1.10 (1.04,1.18)** | **1.06 (1.02,1.11)** |
| > 7 | **1.26 (1.21,1.32)** | **1.24 (1.16,1.32)** | **1.23 (1.15,1.32)** | 1.01 (0.96,1.05) |
| Number of visits to assigned provider | | | | |
| 1–3 | ref | ref | ref | |
| 4–7 | **1.13 (1.09,1.18)** | **1.08 (1.02,1.15)** | **1.1 (1.04,1.16)** | 1 (0.96,1.04) |
| > 7 | **1.25 (1.19,1.31)** | **1.26 (1.17,1.35)** | **1.12 (1.04,1.12)** | **0.89 (0.84,0.93)** |
| Time exposure method continuity of any provider<sup>3</sup> | | | | |
| No | 0.92 (0.83,1.02) | 0.88 (0.74,1.05) | 0.97 (0.84,1.14) | **0.86 (0.77,0.96)** |
| Yes ref | ref | ref | ref | |

ICU, intensive care unit; PCP, primary care physician; OR, odds ratio. CI, confidence interval. All models adjusted for age at diagnosis, gender, race, low socioeconomic status, SEER site, diagnosis year, survival time, Charlson comorbidity score and number of times hospitalized in the 13–24 months prior to diagnosis. Bolded values indicate p < 0.05.

3 = Time exposure method of continuity is defined as having visited the same physician twice within any eight months over the two years prior to the diagnosis of lung cancer.

doi:10.1371/journal.pone.0074690.t003
admissions), but they averaged 1.9 fewer days in the hospital during the last 6 months of life.[26] We did not examine the total number of days spent in the hospital, but whether patients had any hospital or ICU stay during the last month of life.

Inherent to any continuity of care measure, whether based on visit pattern or indices, is the assumption that higher continuity of care leads to greater patient-physician trust. End-of-life decisions are often based on value, preferences and trust between patient and provider. A recent mixed method study of cancer patients showed that “experiencing continuity” involves receiving consistent time and attention, knowing future expectations, managing family consequences, coping between service contacts and believing that nothing has been overlooked.[28] Higher “experienced continuity” is associated with lower care needs. These aspects of continuity are not captured in claims data.

Our study has several limitations. Information on patient preferences and appropriateness of clinical care is not available in claims data. These findings are limited to fee-for-service Medicare beneficiaries and are not generalizable to other populations. A patient’s preferences change following diagnosis of a terminal illness and during the course of his or her disease. Moreover, a recently-diagnosed cancer patient tends to see several new providers in multiple care settings. Our study is limited to advanced lung cancer patients with generally poor survival and the results may not be applicable to patient diagnosed with other cancers. Lack of detailed information on patient’s medical and social status in claims data may have added unmeasured confounding and potential explanation for lack of association between prior continuity and end of life care.

In conclusion, our study showed no consistent association between provider continuity prior to diagnosis of advanced lung cancer and end of life care. Continuity did not substantially reduce potentially inappropriate or increase potentially appropriate care during end of life.

Acknowledgments

The authors thank Sarah Toombs Smith PhD for help in preparation of the manuscript.

This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, NCI, the Office of Research, Development and Information, CMS, Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database.

All authors had access to the data and a role in writing the manuscript. Prior Presentation: None

Author Contributions

Conceived and designed the experiments: GS JG YK JSG. Analyzed the data: YW YK. Contributed reagents/materials/analysis tools: JSG. Wrote the paper: GS YW JG YK JSG.

References

1. 111th Congress. Patient Protection and Affordable Care Act (Public Law 111–148). January 5, 2010. Available: http://www.gpo.gov/fdsys/pkg/PLAW-111publ148/pdf/PLAW-111publ148.pdf.  
2. Saultz JW, Albersdor W (2004) Interpersonal continuity of care and patient satisfaction: a critical review. Ann Fam Med 2(5):445–451.  
3. O’Malley AS, Mandelblatt J, Gold K, Cagney KA, Kern J (1997) Continuity of care and the use of breast and cervical cancer screening services in a multiethnic community. Arch Intern Med 157(13):1462-1470.  
4. Ettner SL (1999) The relationship between continuity of care and the health behaviors of patients: does having a usual physician make a difference? Med Care 37(6):547–555.  
5. O’Malley AS, Mandelblatt J, Gold K, Cagney KA, Kern J (1997) Continuity of care and the use of breast and cervical cancer screening services in a multiethnic community. Arch Intern Med 157(13):1462-1470.  
6. Ettner SL (1996) The timing of preventive services for women and children: the effect of having a usual source of care. JAMA 275(17):1746-1754.  
7. Parchman ML, Burge SK (2004) The patient-physician relationship, primary care attributes, and preventive services. Fam Med 36(1):22-27.  
8. Cheng SH, Chen CC, Hou YF (2010) A longitudinal examination of continuity of care and avoidable hospitalization: evidence from a universal coverage health care system. Arch Intern Med 170(18):1671-1677.

9. Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53(12):1250-1267.

10. Gill JM, Mainous AG III (1998) The role of provider continuity in preventing hospitalizations. Arch Fam Med 7(4):352–357.  
11. Mainous AG III, Gill JM (1998) The importance of continuity of care in the likelihood of future hospitalization: is site of care equivalent to a primary clinician? J Public Health 30(10):1539-1541.  
12. Wasson JH, Sauvage AE, Mogeluck RP, Frey WG, Sox CH, et al. (1984) Continuity of outpatient medical care in elderly men. A randomized trial. JAMA 253(21):2413-2417.  
13. Gill JM, Mainous AG III, Nsoer M (2000) The effect of continuity of care on emergency department use. Arch Fam Med 9(4):333–338.  
14. Goodwin JS, Asrabad A, Howrey B, Giordano S, Kuo YF (2011) Multiple measurement of serum lipids in the elderly. Med Care 49(2):225-230.

15. Wolinsky FD, Bender SE, Liu L, Geweke JF, Cook EA, et al. (2010) Continuity of care with a primary care physician and mortality in older adults. J Gen Intern Med 25(4):421–428.  
16. Reid BC, Rozier RG (2006) Continuity of care and early diagnosis of head and neck cancer. Oral Oncol 42(5):510–516.  
17. Jong TL, Beekelman JE, Liu Y et al. (2010) Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 170(5):440–450.  
18. Burge F, Lawson B, Johnston G (2003) Family physician continuity of care and emergency department use in end-of-life cancer care. Med Care 41(8):992–1001.  
19. Burge F, Lawson B, Johnston G, Cummings I (2003) Primary care-continuity and location of death for those with cancer. J Palliat Med 6(6):911–918.  
20. Sharma G, Freeman J, Zhang D, Goodwin JS (2009) Continuity of care and intensive care unit use at the end of life. Arch Intern Med 169(1):81–86.  
21. Wolinsky FD, Miller TR, Geweke JF, Chrischilles EA, An H, et al. (2007) An interpersonal continuity of care measure for Medicare Part B claims analyses. J Gen Intern Med 22(3):S160-S161.  
22. Mainous AG III, Kern D, Hainer B, Kneuper-Hall R, Stephens J, et al. (2004) The relationship between continuity of care and trust with stage of cancer at diagnosis. Fam Med 36(1):35–39.  
23. Holli K, Hakama M (1993) Continuity of the doctor/patient relationship during the routine follow-up of a breast cancer patient. Support Care Cancer 1(5):263–265.  
24. Dumont I, Dumont S, Turgeon J (2005) Continuity of care for advanced cancer patients. J Palliat Care 21(1):49-56.  
25. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, et al. (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22(2):315-321.  
26. Kromann AC, Ash AS, Freund KM, Hanchate A, Emanuel EJ (2008) Can primary care visits reduce hospital utilization among Medicare beneficiaries at the end of life? J Gen Intern Med 23(9):1330-1335.  
27. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Adnane S, et al. (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363(3):733-742.  
28. King M, Jones L, Richardson A, Murad S, Irving A, et al. (2008) The relationship between patients’ experiences of continuity of cancer care and health outcomes: a mixed methods study. Br J Cancer 98(5):529-536.